Modality
Nanobody
MOA
TNFi
Target
B7-H3
Pathway
Ferroptosis
NMOSD
Development Pipeline
Preclinical
~Jul 2019
→ ~Oct 2020
Phase 1
~Jan 2021
→ ~Apr 2022
Phase 2
Jul 2022
→ Aug 2031
Phase 2Current
NCT07001943
1,521 pts·NMOSD
2022-07→2031-08·Recruiting
1,521 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2031-08-175.4y awayPh2 Data· NMOSD
Trial Timeline
Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2Q3Q4
P2
Recruit…
Catalysts
Ph2 Data
2031-08-17 · 5.4y away
NMOSD
Recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT07001943 | Phase 2 | NMOSD | Recruiting | 1521 | EDSS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| LLY-4358 | Eli Lilly | Phase 3 | B7-H3 | |
| Ceviglumide | Roche | NDA/BLA | B7-H3 | |
| AZN-7403 | AstraZeneca | Phase 2/3 | FGFR | |
| SNY-9600 | Sanofi | NDA/BLA | B7-H3 | |
| SNY-8628 | Sanofi | NDA/BLA | B7-H3 | |
| SNY-9073 | Sanofi | Phase 2 | B7-H3 | |
| NVO-7840 | Novo Nordisk | Phase 2/3 | B7-H3 | |
| NVO-7872 | Novo Nordisk | NDA/BLA | B7-H3 | |
| TAK-8262 | Takeda | NDA/BLA | Tau | |
| DSN-5254 | Daiichi Sankyo | Phase 1 | B7-H3 |